Novo Nordisk CEO talks soaring weight-loss drug demand, Q1 earnings

Novo Nordisk CEO on Q4 results, soaring demand for Wegovy and OzempicПодробнее

Novo Nordisk reports Q1 profits o $3.65 BN as demand for weightloss drug soarsПодробнее

Novo Nordisk CEO Talks Weight Loss Drug Supply | Bloomberg TalksПодробнее

Novo Nordisk CEO on Wegovy, Ozempic Supplies and PricingПодробнее

Novo Nordisk CEO on Catalent, Ozempic and WegovyПодробнее

Novo Boosts Profit Outlook on Obesity Drug DemandПодробнее

How Ozempic And Wegovy Accidentally Made Novo Nordisk A $400B CompanyПодробнее

Novo Nordisk record profits with weight-loss-drug demand boostПодробнее

Top exec at maker of Ozempic, Wegovy talks surging demandПодробнее

Former FDA commissioner: Expect more competition in Eli Lilly and Novo Nordisk's weight-loss drugsПодробнее

Obesity drug maker Novo Nordisk lifts outlook again | REUTERSПодробнее

Mizuho's Holz on weight loss drugs: Lilly and Novo Nordisk are in excellent shape fundamentallyПодробнее

Novo Nordisk cuts some supply of Wegovy obesity drug as demand growsПодробнее

Ozempic Maker Novo Nordisk Has Denmark’s Economy HookedПодробнее

Weight-Loss Drugs Ozempic, Wegovy Propel Novo Nordisk Into SpotlightПодробнее

New developments in weight-loss drugs: Novo Nordisk, Eli Lilly & Pfizer advance studiesПодробнее

Novo Nordisk CEO on safety concerns associated with off-label use of diabetes drugsПодробнее

Ozempic is a game-changer. Here’s how it works.Подробнее